EE30 Economic Impact of Trilaciclib for Chemotherapy-Induced Myelosuppression (CIM) in Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Economic Evaluation from the Provider and Patient-Caregiver Perspectives in the United States
Abstract
Authors
I Abraham W Xue X Chen J Zhou H Huang